hepatitis C

These 2 Biotech Stocks Are Set To Split The $15 Billion Hepatitis C Market
Yahoo/Benzinga
Fri, 12/12/14 - 07:17 pm
hepatitis C
Gilead Sciences
Sovaldi
Harvoni
AbbVie
Why Gilead Sciences and AbbVie Care About This Tiny Company
Motley Fool
Thu, 12/11/14 - 10:32 am
AbbVie
Gilead Sciences
Achillion
hepatitis C
Gilead sued over 'exorbitant' hepatitis C drug prices
Yahoo/Reuters
Wed, 12/10/14 - 05:50 pm
Gilead
hepatitis C
drug pricing
Harvoni
Sovaldi
Gilead Sciences: Still Waiting on AbbVie
Barron's
Tue, 12/9/14 - 04:03 pm
Gilead Sciences
AbbVie
hepatitis C
Gilead Sciences: Time to Look Beyond Hepatitis C?
Barron's
Fri, 12/5/14 - 10:30 am
Gilead Sciences
hepatitis C
Johnson & Johnson Bought Alios for Hepatitis C
Motley Fool
Thu, 12/4/14 - 10:41 am
JNJ
Alios BioPharma
M&A
hepatitis C
Costly Hepatitis ‘C’ Drug Makers Face New Fire
Yahoo/The Fiscal Times
Thu, 12/4/14 - 10:13 am
hepatitis C
drug pricing
Harvoni
Sovaldi
Bristol-Myers Squibb Foundation Awards Nine Grants Totaling More than $3.5 Million to Support Care for High-Risk Patients with Hepatitis B and C in China and India
Yahoo
Wed, 12/3/14 - 10:03 am
Bristol-Myers Squibb
India
grants
hepatitis B
hepatitis C
Sovaldi Versus Abbvie Combination: Analysis Of Abbvie Combination Impact On Sovaldi Market Share
Seeking Alpha
Tue, 12/2/14 - 08:54 am
Sovaldi
AbbVie
Gilead Sciences
hepatitis C
Why Gilead Sciences, Inc. Stock Lost 10% in November
Motley Fool
Tue, 12/2/14 - 08:49 am
Gilead Sciences
Sovaldi
Harvoni
hepatitis C
Gilead Sciences: New Prescriptions for Hepatitis C Drugs Slow
Barron's
Sat, 11/29/14 - 10:27 am
Gilead Sciences
hepatitis C
Harvoni
Sovaldi
FDA declines to approve Bristol-Myers hepatitis drug
Yahoo/Reuters
Wed, 11/26/14 - 12:08 pm
hepatitis C
Bristol-Myers Squibb
FDA
daclatasvir
Can Partnering To Fight Hepatitis C Pay At Enanta?
Investors.com
Mon, 11/24/14 - 06:23 pm
hepatitis C
Enanta
paritaprevir
Europe gives green light to AbbVie hepatitis C medicine, others
Yahoo/Reuters
Fri, 11/21/14 - 08:11 am
Europe
AbbVie
hepatitis C
dasabuvir
Sanofi
eliglustat
Novartis
secukinumab
Merck
Vorapaxar
Boehringer Ingelheim
nintedanib
World’s Drug Bill Will Reach $1.3 Billion in 2018: Study
Bloomberg
Thu, 11/20/14 - 08:21 am
drug pricing
hepatitis C
Gilead Sciences: The Worst Case Scenario?
Barron's
Wed, 11/19/14 - 05:31 pm
Gilead Sciences
hepatitis C
Harvoni
Sovaldi
Gilead Sciences (GILD) Stock Rises After European Commission Market Authorization for Harvoni
TheStreet.com
Tue, 11/18/14 - 10:59 am
Gilead Sciences
Harvoni
Europe
hepatitis C
Gilead: What About Its Pipeline?
Barron's
Mon, 11/17/14 - 10:52 am
Gilead Sciences
hepatitis C
4 Top Pharmaceutical Companies Helping Combat Hepatitis C Near Epidemic
24/7 Wall St
Thu, 11/13/14 - 09:34 am
hepatitis C
AbbVie
Achillion
Gilead Sciences
Merck
Bristol-Myers Gives Updates on HCV Candidate Daclatasvir
Yahoo/Zacks.com
Wed, 11/12/14 - 08:33 am
Bristol-Myers Squibb
hepatitis C
daclatasvir

Pages